# Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

> **NCT06682156** · — · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 50 (estimated)

## Conditions studied

- Newly Diagnosed Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT06682156
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682156, "Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06682156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*